Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Cytomx Therapeutics Inc | 57 |
| 2 | Council of Scientific and Industrial Research | 12 |
| 3 | Oncternal Therapeutics Inc | 10 |
| 4 | University of Tennessee System | 10 |
| 5 | Massachusetts Institute of Technology | 9 |
| 6 | Memorial Sloan Kettering Cancer Center | 9 |
| 7 | ETH Zurich | 8 |
| 8 | Dana Farber Cancer Institute Inc | 7 |
| 9 | Columbia University | 6 |
| 10 | Incanthera Ltd | 6 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 204 |
| 2 | A61K | Medicinal preparations | 197 |
| 3 | C07K | Peptides | 120 |
| 4 | C07D | Heterocyclic compounds | 87 |
| 5 | C07C | Acyclic and carbocyclic compounds | 42 |
| 6 | C07F | Organometallic compounds | 34 |
| 7 | C07B | General methods of organic chemistry | 19 |
| 8 | G01N | Investigating / analysing materials | 17 |
| 9 | C12N | Microorganisms, enzymes | 15 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 14 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Synthesis of phenstatin and prodrugs thereof | 2005 | 4 | |
| LOCALIZED DELIVERY SYSTEM FOR PHENSTATIN USING N-ISOPROPYLACRYLAMIDE | 2004 | University of Arizona | 2 |
| SYNTHESIS OF PHENSTATIN AND PRODRUGS THEREOF | 2003 | 0 | |
| SYNTHESIS OF PHENSTATIN AND PRODRUGS THEREOF | 2000 | 0 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Joëlle Dubois | Institut de Chimie des Substances Naturelles | 7 |
| 2 | Alina Ghinet | Université de Lille | 6 |
| 3 | Benoı̂t Rigo | Université de Lille | 6 |
| 4 | Amaury Farce | Université de Lille | 5 |
| 5 | Rafael Peláez | Universidad de Salamanca | 4 |
| 6 | Concepción Álvarez | Universidad de Salamanca | 4 |
| 7 | Philippe Gautret | Université de Lille | 4 |
| 8 | Manuel Medarde | Universidad de Salamanca | 4 |
| 9 | Raquel Álvarez | Universidad de Salamanca | 4 |
| 10 | Ernest Hamel | National Institutes of Health | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Synthesis, biological evaluation, and molecular docking analysis of phenstatin based indole linked chalcones as anticancer agents and tubulin polymerization inhibitors | 2020 | 110 | Synthesis and biological activity |
| Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance | 2017 | 28 | Metal complexes synthesis and properties |
| Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors | 2016 | 21 | Synthesis and biological activity |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of phenstatin?
Which organizations hold the most patents related to phenstatin?
What are the primary research topics associated with phenstatin in the scientific literature?
What is the patent activity trend for phenstatin over recent years?
Which CPC subclasses are most frequently associated with phenstatin patents?